Results 81 to 90 of about 64,886 (293)

CRISPR-Cas systems target endogenous genes to impact bacterial physiology and alter mammalian immune responses

Molecular Biomedicine, 2022
CRISPR-Cas systems are an immune defense mechanism that is widespread in archaea and bacteria against invasive phages or foreign genetic elements.
Qun Wu, Luqing Cui, Yingying Liu, Rongpeng Li, Menghong Dai, Zhenwei Xia, Min Wu   +6 more
doaj   +1 more source

CRISPR-Cas Systems Reduced to a Minimum [PDF]

Molecular Cell, 2019
In two recent studies in Molecular Cell, Wright et al. (2019) report complete spacer integration by a Cas1 mini-integrase and Edraki et al. (2019) describe accurate genome editing by a small Cas9 ortholog with less stringent PAM requirements.
Almendros, Cristóbal, Kieper, Sebastian N., Brouns, Stan J.J.   +2 more
openaire   +3 more sources

Efficient In Vivo Genome Editing Using RNA-Guided Nucleases [PDF]

, 2014
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems have evolved in bacteria and archaea as a defense mechanism to silence foreign nucleic acids of viruses and plasmids.
Fu, Yanfang, Hwang, Woong Y., Joung, J. Keith, Maeder, Morgan L., Peterson, Randall T., Reyon, Deepak, Sander, Jeffry D., Tsai, Shengdar Q., Yeh, J.-R. Joanna   +8 more
core   +1 more source

RIPK4 function interferes with melanoma cell adhesion and metastasis

Molecular Oncology, EarlyView.
RIPK4 promotes melanoma growth and spread. RIPK4 levels increase as skin lesions progress to melanoma. CRISPR/Cas9‐mediated deletion of RIPK4 causes melanoma cells to form less compact spheroids, reduces their migratory and invasive abilities and limits tumour growth and dissemination in mouse models.
Norbert Wronski, Sławomir Lasota, Ewelina Madej, Anna A. Brożyna, Małgorzata Szczygieł, Agnieszka Harazin‐Lechowska, Jan Czerbniak, Janusz Rys, Jaroslaw Czyz, Agnieszka Wolnicka‐Glubisz   +9 more
wiley   +1 more source

CRISPR-Cas Systems in Bacteroides fragilis, an Important Pathobiont in the Human Gut Microbiome

Frontiers in Microbiology, 2017
Background: While CRISPR-Cas systems have been identified in bacteria from a wide variety of ecological niches, there are no studies to describe CRISPR-Cas elements in Bacteroides species, the most prevalent anaerobic bacteria in the lower intestinal ...
Mehrdad Tajkarimi, Hannah M. Wexler, Hannah M. Wexler, Hannah M. Wexler   +3 more
doaj   +1 more source

Application of CRISPR Cas Systems for Biosensing

Biosensors, 2023
The essential properties of a biosensor are its sensitivity and selectivity to detect, monitor and quantify the biomarker(s) for the interests of medicine [...]
Chung Chiun Liu, Yifan Dai
openaire   +3 more sources

Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. [PDF]

, 2018
CRISPR-Cas systems provide microbes with adaptive immunity to infectious nucleic acids and are widely employed as genome editing tools. These tools use RNA-guided Cas proteins whose large size (950 to 1400 amino acids) has been considered essential to ...
Banfield, JF, Burstein, D, Chen, JS, Cofsky, JC, Doudna, JA, Harrington, LB, Kyrpides, NC, Ma, E, Paez-Espino, D, Witte, IP   +9 more
core  

The physicist's guide to one of biotechnology's hottest new topics: CRISPR-Cas

, 2018
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) constitute a multi-functional, constantly evolving immune system in bacteria and archaea cells.
Bonomo, Melia E., Deem, Michael W.
core   +1 more source

Boosting plant immunity with CRISPR/Cas [PDF]

, 2015
CRISPR/Cas has recently been transferred to plants to make them resistant to geminiviruses, a damaging family of DNA viruses. We discuss the potential and the limitations of this method.See related Research: http://www.genomebiology.com/2015/16/1 ...
Chaparro-Garcia, Angela, Kamoun, Sophien, Nekrasov, Vladimir   +2 more
core   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source